Recent

% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

  • lux19insm@rocketmail.com lux19insm Nov 26, 2013 10:48 AM Flag

    iPlex - Novel Therapy to Treat Muscular Dystrophy

    what ever happened with this?
    Researchers Identify Novel Therapy to Treat Muscular Dystrophy

    "Very few studies have utilized the power of combinatorial therapy in the context of muscular dystrophy." said Professor Girgenrath, the study's corresponding author. "While most MD treatments are single-target therapies, we're delving into combinations of different therapies to target multiple pathways."

    The research team studied the outcome of combining the following single mode treatments: increasing regeneration, by overexpressing muscle specific insulin like growth factor-1, IGF-1 and preventing cell death, by inhibiting the expression of Bax, a pro-apoptotic protein. In addition, to test the translational potential of this combination therapy, the researchers systemically treated Bax deficient dystrophic mice with recombinant human IGF-1 (IPLEX TM, manufactured by Insmed Inc).

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • iPlex was drooped manee years ago by Insmed.Sumbody here very stupid and gets da stupid award of the day.

    • On another note, the trial, "Insulin-Like Growth Factor I (IGF-I) in the Prevention of Complications of Preterm Birth" is ongoing, but not recruiting participants. In June of this year, it was estimated that the study completion date and final data collection date for primary outcome measure would occur in December 2013. So it should not be long before the focus is once again on IGF1/BP3 and with it, news on plans for renewed manufacturing.

      • 1 Reply to b_leaguered
      • lux19insm@rocketmail.com lux19insm Nov 26, 2013 11:20 AM Flag

        with a list like this I don't see why they roche would not be making a deal with insm for iplex - and add Muscular Dystrophy to the list

        Aetna considers mecasermin (Increlex) and mecasermin rinfabate (Iplex)* experimental and investigational for the following indications (not an all inclusive list):

        Cardiovascular protection
        Prevention of hearing loss
        Prevention of retinopathy of prematurity
        Treatment of AIDS muscle wasting
        Treatment of amyotrophic lateral sclerosis
        Treatment of Alzheimer's disease
        Treatment of anorexia nervosa
        Treatment of burns
        Treatment of chronic liver disease
        Treatment of Crohn's disease
        Treatment of cystic fibrosis
        Treatment of extreme insulin resistance
        Treatment of HIV-associated adipose redistribution syndrome (HARS)
        Treatment of ischemic heart disease
        Treatment of myotonic muscular dystrophy
        Treatment of osteoporosis
        Treatment of partial GH resistance
        Treatment of spinal cord injury
        Treatment of X-linked severe combined immunodeficiency
        Treatment of Werner syndrome
        Wound healing

 
INSM
12.75+0.42(+3.41%)Feb 9 4:00 PMEST